The company said revenues for the quarter and full-year 2016 included sales of Olerup HLA typing products, which CareDx got through its acquisition of Allenex.
The company also said it has closed a new $25 million debt facility, and will use the proceeds to retire outstanding debt and bolster the launch of AlloSure.
The firm missed analyst estimates for revenues and loss per share, citing a continued investment in its AlloSure NGS test for the wider-than-expected loss.
The company said sales of its AlloMap molecular diagnostic test were negatively affected during the quarter because of reduced collections from an external vendor.
The firm believes the diagnostics industry has not done a good job of communicating the value of medical tests to payors.
By scrutinizing more than 30,000 samples over dozens of studies, the team is exploring the genetics of transplantation complications.
The company reported total revenues of $7.1 million for Q2 and also missed the consensus Wall Street estimate on the bottom line.
The molecular diagnostics firm beat the consensus Wall Street estimate on the top line but missed it on the bottom line.
Diaxonhit, the exclusive European distributor of AlloMap, has selected a laboratory at Strasbourg University Hospitals to perform all testing on the continent.
The test, which indicates risk of heart transplant rejection, is now available to patients in 11 additional states.
A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.
Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.
Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.
In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.